High Compliance in Postmarketing Studies Reinforces Lifecycle Regulation by the FDA

Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA

Overview

Recent data from the FDA highlight a high level of compliance among pharmaceutical companies in fulfilling Postmarketing Requirements (PMRs) and Postmarketing Commitments (PMCs). This trend reinforces the effectiveness of lifecycle-based regulatory frameworks and the growing maturity of global pharmacovigilance systems.

Introduction

Regulatory approval is no longer the final milestone in a product’s journey—it marks the beginning of continuous monitoring in real-world conditions. The FDA requires companies to conduct postmarketing studies to further evaluate safety, efficacy, and product performance across broader populations.

PMRs (mandatory) and PMCs (voluntary commitments) play a critical role in ensuring that the benefit-risk profile of approved products remains favorable over time.

Encouragingly, recent reports indicate that most companies are meeting these obligations, reflecting increased regulatory alignment and operational readiness.

Key Insights

Understanding PMRs and PMCs

Postmarketing Requirements (PMRs): Legally required studies imposed by the FDA, often linked to accelerated approvals or specific data gaps.

Postmarketing Commitments (PMCs): Studies voluntarily agreed upon by sponsors, supporting additional data generation without legal obligation.

Both mechanisms are essential tools to ensure continued product evaluation after market entry.

Strong Compliance Trends

Recent findings show that:

  • Most PMR and PMC studies are progressing on schedule
  • Companies are demonstrating improved tracking and reporting practices
  • There is increased organizational readiness to manage post-approval obligations

This reflects a significant shift toward proactive lifecycle management.

Impact on Pharmacovigilance

High compliance directly strengthens pharmacovigilance systems by enabling:

  • Early detection of rare or long-term adverse events
  • Continuous safety monitoring in real-world settings
  • Evidence-based regulatory actions (e.g., label updates, risk minimization measures)

Pharmacovigilance is no longer reactive—it is a strategic pillar of product lifecycle management.

Validation of Lifecycle Regulation

The lifecycle regulation approach adopted by the FDA emphasizes continuous oversight from development through post-approval.

The observed compliance trends:

  • Validate the effectiveness of this model
  • Reduce post-approval uncertainty
  • Strengthen trust between regulators and industry

This framework is increasingly influencing other global authorities, including the ANVISA.

Implications for Global and Emerging Markets

For companies operating in regulated markets such as Brazil and across Latin America, these developments signal that:

  • Robust pharmacovigilance systems are no longer optional
  • Dedicated resources for postmarketing studies are essential
  • Inspection readiness and compliance culture must be strengthened

Regulatory convergence is expected to further expand these requirements globally.

The message for industry is clear:

Regulatory success does not end at approval—it depends on an ongoing commitment to evidence generation and patient safety.

Conclusion

The high level of compliance with PMRs and PMCs demonstrates that the FDA lifecycle regulation model is both effective and sustainable.

Postmarketing studies are no longer seen as a regulatory burden, but as a strategic component of product success, ensuring continuous safety, regulatory confidence, and patient protection.

GRP can act as your local Agent & Register your product in U.S

Contact our team today to Inquire!

 Email: info@globalregulatorypartners.com

Telephone : (+1) 781-672-4200

References

📩 Connect with us to discuss your INTERACT strategy.

About Global Regulatory Partners

Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices, pharmaceutical, cosmetic and Food Supplement companies globally.

GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, Mexico and South Korea. GRP helps many life science companies register their products in different countries in compliance with local regulations. 

Follow GRP on Social Media !

Subscribe to our Blogs & Newsletter

Share This Post: